Rakuten Medical vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Rakuten Medical is a biotech developing photoimmunotherapy cancer treatment using its Illuminox platform (cetuximab sarotalocan), approved in Japan for head and neck cancer and in clinical trials globally; listed on Tokyo Stock Exchange (TYO: 4707);
About
Rakuten Medical, Inc. is a biotechnology company founded by Yoshihiro Seto in 2006 (as Aspyrian Therapeutics, renamed Rakuten Medical after acquisition by Rakuten Group) and headquartered in San Diego, California, with primary R&D and commercial operations in Japan. The company is focused on developing cancer treatments using its proprietary photoimmunotherapy (PIT) platform, branded as Illuminox. Photoimmunotherapy combines a targeted antibody conjugated to a photoabsorber dye that, when activated by near-infrared light, selectively destroys cancer cells in the illuminated region while minimizing damage to surrounding healthy tissue — a precision oncology approach distinct from traditional chemotherapy or immunotherapy.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.